Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia, Pediatric
B Cell Lymphoma
Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Autologous CD22 CAR T

First Posted Date: 2019-09-13

Last Posted Date: 2024-02-12

Lead Sponsor: Stanford University

Target Recruit Count: 10

Registration Number: NCT04088864

Locations: 🇺🇸
Stanford Medical Center, Stanford, California, United States

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Phase 1

Active, not recruiting

Conditions: B-ALL
DLBCL
Follicular Lymphoma Grade 3B
B-cell Non Hodgkin Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: CD22 CAR

First Posted Date: 2019-09-13

Last Posted Date: 2024-07-25

Lead Sponsor: Stanford University

Target Recruit Count: 52

Registration Number: NCT04088890

Locations: 🇺🇸
Stanford Medical Center, Stanford, California, United States

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Phase 1

Suspended

Conditions: Non-Malignant Neoplasm

Interventions: Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Lapine T-Lymphocyte Immune Globulin
Radiation: Total-Body Irradiation
Procedure: Hematopoietic Cell Transplantation
Drug: Mycophenolate Mofetil
Drug: Sirolimus
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2019-09-10

Last Posted Date: 2024-12-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT04083183

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Biological: ATLCAR.CD30 T cells
Drug: Bendamustine
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-09-10

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT04083495

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Phase 2

Terminated

Conditions: Acute Megakaryoblastic Leukemia
Acute Myeloid Leukemia
Hematopoietic and Lymphoid Cell Neoplasm
HIV Infection
Acute Erythroid Leukemia
Myelodysplastic Syndrome With Excess Blasts
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Drug: Thiotepa
Procedure: Umbilical Cord Blood Transplantation
Biological: Dilanubicel

First Posted Date: 2019-09-10

Last Posted Date: 2025-01-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04083170

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Cleveland Cord Blood Center, Cleveland, Ohio, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 2 locations

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Phase 1

Active, not recruiting

Conditions: Recurrent Anaplastic Large Cell Lymphoma
Recurrent Mycosis Fungoides
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Mycosis Fungoides
Refractory Anaplastic Large Cell Lymphoma
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Anti-CD30/CD16A Monoclonal Antibody AFM13
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
Biological: Genetically Engineered Lymphocyte Therapy

First Posted Date: 2019-08-30

Last Posted Date: 2024-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04074746

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: TIL
Drug: Interleukin-2
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-08-09

Last Posted Date: 2024-06-12

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 9

Registration Number: NCT04052334

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Phase 1

Conditions: Leukemia Lymphocytic Acute (ALL) in Relapse
Leukemia Lymphocytic Acute (All) Refractory
Lymphoma, B-Cell
CD19 Positive

Interventions: Genetic: XYF19 CAR-T cell
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-07-30

Last Posted Date: 2019-07-30

Lead Sponsor: Xijing Hospital

Target Recruit Count: 40

Registration Number: NCT04037566

Locations: 🇨🇳
Xijing Hospital, Xi'an, Shannxi, China

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma, Relapsed
Chronic Lymphoid Leukemia in Relapse
Non-Hodgkin's Lymphoma Refractory
Chronic Lymphocytic Leukemia
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic
B-cell Chronic Lymphocytic Leukemia
B-cell Non Hodgkin Lymphoma
Small Lymphocytic Lymphoma

Interventions: Genetic: PBCAR20A
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-07-23

Last Posted Date: 2023-01-31

Lead Sponsor: Precision BioSciences, Inc.

Target Recruit Count: 18

Registration Number: NCT04030195

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 2 locations

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Phase 1

Withdrawn

Conditions: CD22 Positive
Progressive Disease
Refractory Chronic Lymphocytic Leukemia
Recurrent Non-Hodgkin Lymphoma
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Refractory Non-Hodgkin Lymphoma
CD19 Positive
Minimal Residual Disease

Interventions: Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-07-23

Last Posted Date: 2023-08-21

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04029038

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy